18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)
S Stroobants, J Goeminne, M Seegers… - European journal of …, 2003 - Elsevier
Imatinib mesylate (Glivec®, formerly STI571) is the first effective systemic treatment for
gastrointestinal stromal tumours (GISTs). Major changes in tumour volume, however, tend to occur …
gastrointestinal stromal tumours (GISTs). Major changes in tumour volume, however, tend to occur …
[HTML][HTML] Randomized phase II study of the anti–epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with …
…, A Pęgo, A Chan, JC Goeminne… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
… Stemmer, António Pęgo, Jean-Charles Goeminne, Marie-Pascale Graas, Eva Maria Ciruelos
Gil, Andreas Schneeweiss, Angela Zubel, Ahmad Awada … Baselga J Norton L Masui H , etal …
Gil, Andreas Schneeweiss, Angela Zubel, Ahmad Awada … Baselga J Norton L Masui H , etal …
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
…, P Schatteman, N Lumen, L Dirix, JC Goeminne… - The Lancet …, 2022 - thelancet.com
Background Metastatic castration-resistant prostate cancers are enriched for DNA repair
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …
[HTML][HTML] Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 …
…, JC Goeminne, V Hersberger, J Baselga - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal
growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the …
growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the …
Pitfalls in the detection of disseminated non-hematological tumor cells
JC Goeminne, T Guillaume, M Symann - Annals of oncology, 2000 - Elsevier
There is not yet a consensus on the reliability of the methods that should be used for the
detection of rare disseminated tumor cells from non-hematological malignancies. In this review, …
detection of rare disseminated tumor cells from non-hematological malignancies. In this review, …
[HTML][HTML] Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular …
…, JM Vandenbulcke, N Whenham, JC Goeminne… - Annals of oncology, 2012 - Elsevier
Background This phase II study assessed the safety and efficacy of everolimus, an oral
mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell (TCC) after …
mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell (TCC) after …
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
…, C Hart, A Zhang, H Prenen, JC Goeminne… - The Lancet …, 2023 - thelancet.com
Background FGFR alterations are reported across various malignancies and might act as
oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine …
oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine …
[HTML][HTML] Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis
…, J Verheezen, A Rutten, P Vuylsteke, JC Goeminne… - ESMO open, 2020 - Elsevier
Background Cancer seems to have an independent adverse prognostic effect on COVID-19-related
mortality, but uncertainty exists regarding its effect across different patient subgroups…
mortality, but uncertainty exists regarding its effect across different patient subgroups…
[HTML][HTML] Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium
…, S Luce, G Debugne, H Van den Bulck, JC Goeminne… - Annals of …, 2018 - Elsevier
Background In the general older population, geriatric assessment (GA)-guided treatment
plans can improve overall survival, quality of life and functional status (FS). In GA-related …
plans can improve overall survival, quality of life and functional status (FS). In GA-related …
Phase II study of dual phosphoinositol‐3‐kinase (PI 3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ 235 in patients with locally advanced or metastatic …
…, S Rottey, B Filleul, P Glorieux, JC Goeminne… - BJU …, 2016 - Wiley Online Library
Objective To assess, in a multicentre phase II trial, the safety and efficacy of BEZ 235, an oral
pan‐class I phosphoinositol‐3‐kinase ( PI 3K) and mammalian target of rapamycin ( mTOR …
pan‐class I phosphoinositol‐3‐kinase ( PI 3K) and mammalian target of rapamycin ( mTOR …